Reply to Anthony Et Al., “Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment”

Antimicrobial Agents and Chemotherapy- United States

doi 10.1128/aac.00427-17

Full Text

Abstract

Available in

Date

Authors

Publisher

American Society for Microbiology

Related search

Pyrazinamide May Improve Fluoroquinolone-Based Treatment of Multidrug-Resistant Tuberculosis

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2012English

Erratum for Velásquez Et Al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients With Multidrug-Resistant Tuberculosis

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2017English

Value of Pyrazinamide for Composition of New Treatment Regimens for Multidrug-Resistant Mycobacterium Tuberculosis in China

BMC Infectious Diseases
Infectious Diseases
2020English

Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis

PLoS ONE
Multidisciplinary
2009English

Treatment Outcomes of Rifabutin-Containing Regimens for Rifabutin-Sensitive Multidrug-Resistant Pulmonary Tuberculosis

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2017English

Revolutionary New Treatment Regimens for Multidrug-Resistant Tuberculosis

The Lancet Infectious Diseases
Infectious Diseases
2019English

Clofazimine for the Treatment of Multidrug-Resistant Tuberculosis

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2019English

Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB Among Treatment Failures

PLoS ONE
Multidisciplinary
2007English

Bedaquiline: New Approach for Treatment of Multidrug-Resistant Tuberculosis

RUHS Journal of Health Science
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy